contemporary siRNA therapeutics and the current state-of-art

Current Pharmaceutical Design

Volumn 21, Issue 31, 2015, Pages 4527-4528

  Tekade, Rakesh K ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

NANOCARRIER; SMALL INTERFERING RNA;

BRAIN DISEASE; CELL MEMBRANE; DISSOCIATION; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; EDITORIAL; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; EYE DISEASE; GENE SILENCING; GENE TARGETING; HUMAN; MOLECULAR SIZE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; SKIN DISEASE; TREATMENT RESPONSE;

GENE SILENCING; HUMANS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84946750622     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821999150911093912     Document Type: Editorial

References (16)

1. [1] Kim YM, Park MR, Song SC. An injectable cell penetrable nano-polyplex hydrogel for localized siRNA delivery. Biomaterials 2013; 34: 4493-500.
2. [2] Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release 2014; 28: 238-56.
3. [3] Seo MJ, Lee JJ, Kim HO, et al. Detection of internal mammary lymph node metastasis with F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer. Eur J Nucl Med Mol Imaging 2013; 6: 6.
4. [4] Tekade RK, Kumar PV, Jain NK. Dendrimers in oncology: an expanding horizon. Chem Rev 2009; 109: 49-87.
5. [5] Mody N, Tekade RK, Mehra NK, Chopdey P, Jain NK. Dendrimer, liposomes, carbon nanotubes and PLGA nanoparticles: one platform assessment of drug delivery potential. AAPS PharmSciTech 2014; 15: 388-99.
6. [6] Karunaratne DN, Jafari M, Ranatunga RJKU, Siriwardene A. Natural carriers for siRNA delivery. Curr Pharm Des 2015; 21(31): 4529-40.
7. [7] Vhora I, Patil S, Amrutiya J, Misra A. Liposomes and Lipid envelope-type systems for systemic siRNA delivery. Curr Pharm Des 2015; 21(31): 4541-55.
8. [8] Kumar L, Verma S, Vaidya B, Gupta V. Exosomes: natural carriers for siRNA delivery. Curr Pharm Des 2015; 21(31): 4556-65.
9. [9] Salzano G, Costa DF, Torchilin VP. siRNA delivery by stimuli-sensitive nanocarriers. Curr Pharm Des 2015; 21(31): 4566-73.
10. [10] González-Rodríguez A., Valverde AM. RNA interference as a therapeuthic strategy for the treatment of liver diseases. Curr Pharm Des 2015; 21(31): 4574-86.
11. [11] Kataki MS, Kakoti BB, Jameson M, Solanki A, Hirani A, Pathak Y. Nanoplatforms for delivery of siRNA to the eye. Curr Pharm Des 2015; 21(31): 4587-93.
12. [12] Aldawsari M, Chougule MB, Babu RJ. Progress in topical siRNA delivery approaches for skin disorders. Curr Pharm Des 2015; 21(31): 4594-605.
13. [13] Mohanty C, Kundu P, Sahoo SK. Brain targeting of siRNA via intranasal pathway. Curr Pharm Des 2015; 21(31): 4606-13.
14. [14] Tekade RK, Tekade M, Kumar M, Chauhan AS. Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics. Pharm Res 2015; 32: 910-28.
15. [15] Tekade RK, Maheshwari RGS, Sharma PA, Tekade M, Chauhan AS. siRNA therapy, challenges and underlying perspectives of dendrimer as delivery vector. Curr Pharm Des 2015; 21(31): 4614-36.
16. [16] Kim Y-D, Park T-E, Singh B, et al. Image guided nanoparticle based siRNA delivery for cancer therapy. Curr Pharm Des 2015; 21(31): 4637-56.